Barrett's Oesophagus Two Yearly Surveillance Versus Endoscopy at Need: a Randomised Controlled Trial to Estimate Effectiveness and Cost-effectiveness Study (BOSS)
试验速览
- 阶段
- 不适用
- 入组人数
- 3,400
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment. It is not yet known whether endoscopy every 2 years is more effective than endoscopy only as needed in finding esophageal cancer in patients with Barrett esophagus.
PURPOSE: This randomized phase III trial is studying endoscopy every 2 years to see how well it works compared with endoscopy only as needed in monitoring patients with Barrett esophagus.
详细描述
OBJECTIVES:
Primary
- To establish whether endoscopic surveillance every 2 years or endoscopy at need only is superior in terms of overall survival and, if neither is superior, whether endoscopy at need only is non-inferior to surveillance every 2 years in patients with Barrett esophagus.
Secondary
- To estimate the cost-effectiveness of endoscopic surveillance every 2 years as compared to endoscopy at need only.
- To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the incidence of esophageal cancer, gastric or esophageal cancer, or all cancers.
- To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the time to diagnosis of esophageal adenocarcinoma.
- To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the stage of esophageal adenocarcinoma at diagnosis using TNM staging.
- To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of morbidity and mortality related to endoscopy, esophageal surgery, and other endoscopy-related interventions (e.g., ablation).
- To establish whether there is a significant difference between endoscopic surveillance every 2 years or endoscopy at need only in terms of the frequency of endoscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
2 yearly endoscopies
Two years endoscopies
干预措施: comparison of screening methods (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: endoscopic biopsy (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: diagnostic endoscopic procedure (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: 2 yearly endoscopy (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: endoscopic procedure (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: quality-of-life assessment (Procedure)
2 yearly endoscopies
Two years endoscopies
干预措施: screening method (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: 2 yearly endoscopy (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: comparison of screening methods (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: diagnostic endoscopic procedure (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: endoscopic biopsy (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: endoscopic procedure (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: quality-of-life assessment (Procedure)
endoscopy at need
Endoscopy only when patient reports symptoms
干预措施: screening method (Procedure)
结局指标
主要结局
Overall survival
次要结局
- Time to diagnosis of esophageal adenocarcinoma
- Frequency of endoscopy
- Morbidity and mortality related to endoscopy, esophageal surgery, and other endoscopy-related interventions
- Stage of esophageal adenocarcinoma at diagnosis using TNM staging
- Cost-effectiveness
- Incidence of esophageal cancer, gastric or esophageal cancer, or all cancers
研究者
Clive Stokes
Professor Hugh Barr
Gloucestershire Hospitals NHS Foundation Trust
